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3THE ECONOMIC IMPLICATIONS OF NON-
COMPLIANCE AFTER RENAL
TRANSPLANTATION
Cleemput I1, De Geest S2,Vanrenterghem Y3, Kesteloot K4
1Katholieke Universiteit Leuven, Leuven, Belgium; 2University
of Basel, Basel, Switzerland; 3University Hospitals Leuven,
Leuven, Belgium; 4Catholic University Leuven, Leuven,
Belgium
OBJECTIVES: The economic impact of therapeutic non-
compliance in chronic diseases has rarely been examined
following qualitative standards for economic evaluation.
This study illustrates the potential impact of non-
compliance on the cost-utility of chronic treatments using
the case of renal transplantation versus haemodialysis and
examines the economic scope for compliance enhancing
interventions. METHODS: Long term cost and outcomes
in compliant and noncompliant renal transplant pa-
tients were simulated in a Markov model. The cost 
and outcome data that were imputed in the model were
derived from a prospective study in renal transplantation
candidates. Probabilities of adverse events, graft rejection,
graft loss and death, in compliant and noncompliant renal
transplant patients were derived from literature. A soci-
etal viewpoint was taken. RESULTS: Compared with
dialysis, renal transplantation offers a better outcome 
in both compliant and non-compliant patients. Lifetime
costs after transplantation in the compliant patient group
are higher than lifetime dialysis costs and than life-time
costs in the non-compliant patient group, mainly because
compliant patients live longer after transplantation.
Long-term outcomes after transplantation are better for
compliant than for non-compliant patients. The mean
cost per quality-adjusted life-year gained (QALY) in 
compliant patients relative to non-compliant patients 
is €36,606.94/QALY (95% conﬁdence interval
[35,157.13–37,986.57]). CONCLUSIONS: This study
shows that renal transplantation is an optimal treatment
for end stage renal disease patients, regardless of patients’
level of compliance post-transplantation, as illustrated 
by the lower costs and better outcomes. In view of 
the incremental cost-utility ratio of haemodialysis, which 
is considered to be a cost-effective treatment, of
€65,912/QALY, it can be concluded that there is scope for
compliance- enhancing interventions. The improvement
of outcome in compliance justiﬁes the additional costs





POLICIES FOR INCLUSION OF DRUGS FOR
REIMBURSEMENT BY THE PHILIPPINE HEALTH
INSURANCE CORPORATION
Valera MR
Philippine Health Insurance Corporation, Pasig, Philippines
OBJECTIVES: The Health Technology Assessment
(HTA) Committee of the Philippine Health Insurance
Corporation (PhilHealth) was established in 1999 to
develop reimbursement policies on medical claims based
on the cost-effectiveness of tests and treatments. ME-
THODS: The most commonly prescribed drugs that 
PhilHealth does not reimburse are subjected to this assess-
ment Because randomized controlled trials provide the
best evidence of efﬁcacy and effectiveness, only system-
atic reviews of RCTs and individuals RCTs are included.
The intervention in the study should have at least the drug
being evaluated in one arm and a standard treatment in
the other arm. Electronic search is done through the Inter-
net in the MEDLINE by two independent searchers. Elec-
tronic search is also done in the CD version of the
Cochrane Library Two independent reviewers review all
abstracts and articles for possible inclusion. The full texts
of the selected abstracts are retrieved at a library network.
Two reviewers using a standard assessment form inde-
pendently assess the validity and applicability of the
included systematic reviews and clinical trials. Qualitative
and if appropriate, quantitative methods are used to
analyze and/or combine the results of the different studies
in order to come up with a summary measure of effec-
tiveness. RESULTS: Safety and cost-effectiveness data 
are obtained from the results of clinical trials, post-
marketing surveillance studies, ADR reports from local
and international sources and local retail drug costs.
CONCLUSIONS: If the drug is less cost-effective or safe
than the standard drug, then it is not recommended for
inclusion in the PhilHealth positive list of reimbursable
drugs. If the drug is more cost-effective and poses no addi-
tional risk compared with the standard drug, then the
drug is recommended for inclusion in the positive list pro-
vided that it is used for the conditions for which it was
found effective.
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1GlaxoSmithKline, Espoo, Finland; 2Pharma Industry Finland,
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OBJECTIVES: To describe the development of drug
wholesale price indices in Finland during in 1980–2002.
METHODS: Price indices covering study time span (The
Helsinki Research Institute for Business Administration
[1980–1990], IMS [1991–1994] and Statistics Finland
[1995–2002]) were combined to reliable price indices that
reﬂect the development of drug prices in general and in
different reimbursement categories. Two different index
clusters (1980 = 100 and 1990 = 100) were produced.
The latter enables more precise classiﬁcation of different
reimbursement categories. After constructing the nominal
indices, real price indices were produced by adjusting
nominal indices with Consumer Price Index (CPI, Statis-
tics Finland) and its sub-index Consumer Price Index for
Health Care (CPI-H, Statistics Finland). RESULTS: In
2002 the index (1980 = 100) for all drugs was 168 (CPI
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adjusted 70 and CPI-H adjusted 40) and for basic refund
category 147 (61; 35), respectively. In 1990 = 100 index
the respective ﬁgures were: all drugs 110 (88; 68), pre-
scription based 105 (83; 64), reimbursed 102 (81; 62),
Basic Refund (“50%”) 102 (81; 62), Lower Special
Refund (“75%”) 102 (81; 62) and Higher Special Refund
(“100%”) 103 (82; 63). CONCLUSIONS: Nominal drug
wholesale prices have increased in Finland since 1980 and
also slightly from 1990, but real prices have constantly
decreased. Depending from the adjustment index used,
the real prices of all drugs have decreased from 30–60%
since 1980, or 12–33% since 1990. For reimbursed drugs
the development was similar. The prices in general, and
in the Basic Refund category have decreased 19–38%
since 1990, and even 40–75% since 1980. Since the effec-
tiveness of drugs has not decreased during the time period
studied, we suggest that the drug treatment has clearly
become more cost-effective in Finland.
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COMPARISON OF MARKET EXCLUSIVITY OF
PHARMACEUTICALS IN CANADA, THE UNITED
STATES, THE UNITED KINGDOM AND FRANCE
Palmer WN, Neale S, Salazar A
Palmer D’Angelo Consulting Inc, Ottawa, ON, Canada
OBJECTIVES: To compare the periods of market 
exclusivity for branded pharmaceuticals in Canada with
the United States, the United Kingdom, and France.
METHODS: We identiﬁed the 50 top selling generic mol-
ecules in Canada. The dates of ﬁrst sale of the original
brand and corresponding ﬁrst generic for each molecule
were compared to determine the period of market exclu-
sivity of each branded product. Corresponding data were
collected and periods of exclusivity calculated for the US,
UK and France. In cases where a generic had yet to be
introduced in a comparator country, the period of market
exclusivity was calculated as of May 2003. Average
market exclusivity for the products in the study was cal-
culated for each country. RESULTS: The average period
of market exclusivity for the 50 brands in Canada was
10.7 years, considerably lower than in the other countries
(US 12.1; UK 15.0; France 19.1 years). There was incom-
plete international information for nine of the ﬁfty mol-
ecules. When the analysis was restricted to the remaining
41 products the results were similar (Canada 9.8; US
12.0; UK 15.0; France 17.0 years). Although the sample
products represent the 50 top selling generic molecules in
Canada, many were not yet marketed as generics in the
comparator countries (US 6; UK 11; France 21). CON-
CLUSIONS: The analysis indicates that on average,
market exclusivity for the same brands in Canada was
signiﬁcantly shorter than in the US, UK and France. A
more favourable regulatory climate for generic drugs in
Canada (early working, faster generic approval times,
mandatory generic substitution laws etc.) and longer
approval times for brand drugs may account for some 
of the differences. Despite changes in patent legislation
(1987, 1993) to restore patent protection, the analysis
does not suggest a trend toward longer periods of market
exclusivity for newer brands in Canada.
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SPANISH NATIONAL HEALTH SERVICE:
ANALYSIS OF THE INTRODUCTION OF NEW
DRUGS IN THE CLINICAL PRACTICE FROM 1996
TO 2000
Gaspar M, Modamio P, Lastra C, Mariño E
University of Barcelona, Barcelona, Spain
OBJECTIVES: When the selection of treatments ﬁnanced
by public money is considered, rational decisions to incor-
porate a new drug in clinical practice has to be even more
exact. Here, we analyse the incorporation of new medi-
cines ﬁnanced by the Spanish National Health Service
(NHS) into the clinical practice from 1996 to 2000. The
Spanish NHS covers more than 95% of the population.
METHODS: A retrospective study has been made, select-
ing new medicines classiﬁed following the degree of ther-
apeutic innovation at the moment of authorisation (A*,
A, B, C, and D), according to the criterion of the Min-
istry of Health and Consume (MHC). Consume data were
provided by the MHC database. They were expressed as
Price for Sale Direct to Customer, tax-free (PVP) by means
of Millions of Pesetas (MPTA) and in number of con-
sumed units. The rapid incorporation of new medicines
into the clinical practice (the one-hundred tops) and the
evolution of their consume were the indicators used.
RESULTS: The total number of new drugs selected was
68 (19, 20, 19, 8, and 2 in the years 96, 97, 98, 99, and
00, respectively). None of them were categorised in type
A*. Mostly were types B (29.4%) and C (67.6%). From
those, Olanzapine (96), Atorvastatin (97), Cerivastatine
(98), Clopidogrel (99), or Celecoxib (00), among others,
had a very fast incorporation. Analysing the evolution of
new drug consumption, it detected that some of them
have been withdrawn from the clinical practice because
of adverse drug events (Ebrotidine (96) in 1998,
Grepaﬂoxacin (98) in 1999 or Cerivastatine (98) in
2001). CONCLUSIONS: The indicators used in this
study have permitted analyse the quality of the selection
of treatments ﬁnanced by public money. From the results
obtained, it would strongly recommend an urgent revi-
sion of type C (67.6%) new drugs ﬁnanced by NHS.
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SURVEY ON DRUG VALUE ASSESSMENT
AMONG PRESCRIBERS AND PAYERS IN ITALIAN
HOSPITALS
Negrini C, D’Ausilio A, Lopatriello S, Berto P
pbe consulting,Verona, Italy
OBJECTIVES: To identify and analyse elements on which
hospital decision makers base their therapy value assess-
ment, both in general terms and in relation to acute Heart
Failure (aHF)treatment. METHODS: Thirty face to face
interviews (15 hospital pharmacists and 15 cardiologists)
